Affiliation:
1. Lancaster University, Centre for the Economic & Social Aspects of Genomics (CESAGen), Institute for Advanced Studies, Lancaster, LA1 4YD, UK.
Abstract
In the last decade, governments, medical charities, pharmaceutical companies and disease advocacy organizations have spent considerable time and money developing biobanks to aid drug discovery and the investigation of disease. This article identifies and assesses the various expectations that have driven the investment in different types of biobanks. It suggests that they have been the focus of unrealistic promises about producing a ‘biobank revolution’ that will transform biomedicine and healthcare. We need more modest expectations about what can be achieved, and need to tackle certain conceptual and methodological challenges for biobanks to fulfill their potential.
Subject
Pharmacology,Molecular Medicine,General Medicine
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献